Can Process Analytical Technologies (PATs) Really Improve Your CGT Manufacturing Process?
Wednesday, May 29, 2024 08:00 AM - 09:00 AM
Room 208-209
Roundtable
Organized by: ISCT Process Analytical Technologies (PAT) Subcommittee
Supported by: LumaCyte
Moderator
Leverage key takeaways from ISCT's survey of CGT manufacturers to identify opportunities to leverage PATs to improve CGT processes and products.
Key Learning Objectives
1. Establish the current state of PAT implementation in CGT manufacturing (ref. Survey, expert panelists), with alignment on relevant definitions & terminology (e.g. In-line, on-line, at-line, and off-line).
2. Identify limitations of current solutions and CGT specific challenges for successful PAT implementation.
3. Discuss strategies for addressing CGT specific challenges and the next generation of PAT development for advanced CGT manufacturing.
Supported by: LumaCyte
Moderator
- Dalip Sethi, PhD, MBA, MS, Terumo Blood and Cell Technologies, United States
- Anand Srinivasan, M.S., Ph.D., BioBridge Global, United States
- Fernanda Masri, PhD, Cytomos, United Kingdom
- Sean Hart, PhD, LumaCyte, United States
- Stephanie Davies, PhD, Beckman Coulter Life Sciences - ValitaCell Ltd, Ireland
Leverage key takeaways from ISCT's survey of CGT manufacturers to identify opportunities to leverage PATs to improve CGT processes and products.
Key Learning Objectives
1. Establish the current state of PAT implementation in CGT manufacturing (ref. Survey, expert panelists), with alignment on relevant definitions & terminology (e.g. In-line, on-line, at-line, and off-line).
2. Identify limitations of current solutions and CGT specific challenges for successful PAT implementation.
3. Discuss strategies for addressing CGT specific challenges and the next generation of PAT development for advanced CGT manufacturing.
SPONSORED BY:
